Corporate Spotlight

First Telix and Duchembio Joint Symposium – Emergence of PSMA-PET Imaging in South Korea

22 November 2021 – Clinical Spotlight | Telix and Duchembio announce a joint symposium on 68Ga-PSMA-PET imaging in Korea

With our partner, Duchembio, we are pleased to present a first joint symposium on 68Ga-PSMA-PET prostate cancer imaging in Korea.

PSMA-PET imaging has had a remarkable impact on the management of prostate cancer, and has great potential to extend and improve the lives of men with this condition in Korea.

The symposium entitled: “ 68Ga-PSMA PET Imaging in Prostate Cancer”, will take place on Tuesday 30 November 2021 from 4:00 – 5:30 pm KST / 6:00 – 7.30 pm (AEDT).

Expert speakers Dr. Joshua Morigi, Nuclear Medicine Physician & Head of Nuclear Medicine, Royal Darwin Hospital, Australia, and Professor Louise Emmett, Nuclear Medicine Physician & Director of Department of Theranostics and Nuclear Medicine, St Vincent’s Hospital Sydney, Australia, will bring their extensive experience to a highly engaging session introducing PSMA-PET imaging in prostate cancer.

This interactive session, moderated by Dr. Danielle Meyrick, Telix’s Chief Medical Officer for Asia Pacific, will include case study presentations demonstrating the utility of PSMA-PET, with an approach to imaging interpretation and common pitfalls highlighted. Key clinical studies and guidelines will also be introduced.

If you are interested in attending this event or would like to know more, please contact Duchembio Sales & Marketing on +822-332-4868 and select Extension 1.

To return to the Telix homepage please click here.